Beta Bionics Reports Q4 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy BBNX?
Source: NASDAQ.COM
- Improved Financial Performance: Beta Bionics reported a narrowed net loss of $13.47 million in Q4 2025, down from $18.11 million the previous year, indicating positive progress in cost management and revenue growth, although the full-year net loss widened to $73.20 million, highlighting ongoing concerns about long-term profitability.
- Significant Revenue Growth: The company achieved a 57% year-over-year revenue increase in Q4, reaching $32.12 million, primarily driven by a 295% surge in Pharmacy Benefit Plan channel sales to $9.8 million, which lays a solid foundation for future market expansion and product acceptance.
- Optimistic Future Outlook: Beta Bionics anticipates total revenue for 2026 to be between $130 million and $135 million, reflecting confidence in new patient starts, with an estimated 36% to 38% expected to be reimbursed through the Pharmacy Benefit Plan, indicating strong market demand potential.
- R&D Progress on Track: The company recently completed the first-in-human Phase 2a feasibility trial for its bihormonal system in New Zealand and plans to initiate an additional feasibility trial in the first half of 2026, preparing for advanced-stage development and enhancing its competitive edge in diabetes treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBNX
Wall Street analysts forecast BBNX stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 10.760
Low
17.00
Averages
27.11
High
40.00
Current: 10.760
Low
17.00
Averages
27.11
High
40.00
About BBNX
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beta Bionics Launches Bionic Insights™, Revolutionizing Diabetes Management
- Innovative Reporting: Beta Bionics has launched Bionic Insights™, a new feature within its Bionic Reports designed to assist healthcare providers in making more personalized treatment recommendations for diabetes patients, thereby enhancing treatment outcomes and patient satisfaction.
- Transformative Data Interpretation: This feature goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities, and system events, enabling clinicians to gain clearer insights into patient data and optimize treatment plans.
- Success and Opportunity Identification: Bionic Insights organizes information into areas of success and opportunity, allowing physicians to quickly identify factors influencing glucose outcomes, reducing time spent on raw data interpretation and increasing meaningful patient interactions.
- Mission-Driven Innovation: Beta Bionics is committed to simplifying diabetes management through innovation, and the launch of Bionic Insights marks a significant step in improving patient quality of life and treatment effectiveness.
See More
Faruqi & Faruqi Investigates Beta Bionics for Investor Losses
- Investor Loss Investigation: Faruq & Faruqi, LLP is investigating potential claims against Beta Bionics, aiming to provide legal support for affected investors to help them assert their rights.
- Legal Consultation Opportunity: The firm encourages investors who suffered significant losses in Beta Bionics stock or options to contact partner Josh Wilson directly, offering consultation services to explore legal options and enhance investor awareness of their rights.
- Industry Background: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in the securities law field.
- National Reach: With offices in New York, Pennsylvania, California, and Georgia, the firm demonstrates its capability to provide legal services nationwide, enabling support for investors across various regions.
See More
Faruqi & Faruqi Investigates Beta Bionics for Investor Losses
- Investor Loss Focus: Faruq & Faruq's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Beta Bionics (NASDAQ: BBNX) to reach out directly, indicating the firm's commitment to protecting investor rights.
- Legal Rights Discussion: Investors who have incurred losses in Beta Bionics stock or options can call the hotline at 877-247-4292 or 212-983-9330 (Ext. 1310) for consultation, demonstrating the firm's dedication to client support and service.
- Company Background: Founded in 1995, Faruq & Faruq has recovered hundreds of millions of dollars for investors, showcasing its extensive experience and successful track record in securities law, which enhances investor trust in its capabilities.
- National Legal Services: With headquarters in New York and offices in Pennsylvania, California, and Georgia, the firm demonstrates its ability to provide legal services nationwide, further expanding its client base and market influence.
See More
Faruqi & Faruqi Investigates Beta Bionics Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Beta Bionics, indicating that the company may face legal risks as it seeks to support investors who have suffered significant losses.
- Investor Rights Protection: The firm encourages investors who have incurred losses in Beta Bionics stock or options to contact partner Josh Wilson directly, demonstrating a commitment to safeguarding investor rights.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law.
- Contact Information Provided: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to ensure that affected investors receive timely legal advice and support.
See More
Faruqi & Faruqi Investigates Investor Losses in Beta Bionics
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Beta Bionics to provide legal support for investors who have suffered significant losses, indicating potential legal liabilities for the company.
- Investor Rights Protection: The firm encourages Beta Bionics investors to contact partner Josh Wilson directly, demonstrating its commitment to investor rights and offering legal consultation to help investors understand their options.
- Company Background Information: Beta Bionics is a publicly traded company on NASDAQ involved in the biotechnology sector, and investor losses may be related to operational or financial issues, impacting market confidence.
- Firm's Strength Showcase: Since its founding in 1995, Faruq & Faruq LLP has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in the securities law field.
See More
Faruqi & Faruqi Investigates Beta Bionics After 37% Stock Plunge
- Stock Plunge: Beta Bionics' shares fell approximately 37% on January 9, 2026, primarily due to the company's expectation of fewer patient starts in Q4 than analysts estimated, which undermined investor confidence and may lead to legal action.
- Legal Investigation: Faruq & Faruqi, LLP is investigating whether Beta Bionics issued misleading statements or failed to disclose information critical to investors, aiming to protect investor rights and pursue potential compensation.
- Investor Losses: The law firm encourages investors who suffered significant losses to contact their securities litigation partner, Josh Wilson, directly, indicating the firm's commitment to supporting investors in addressing their losses.
- Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which further enhances investor trust in its investigation.
See More
Beta Bionics Launches Bionic Insights™, Revolutionizing Diabetes Management
- Innovative Reporting: Beta Bionics has launched Bionic Insights™, a new feature within its Bionic Reports designed to assist healthcare providers in making more personalized treatment recommendations for diabetes patients, thereby enhancing treatment outcomes and patient satisfaction.
- Transformative Data Interpretation: This feature goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities, and system events, enabling clinicians to gain clearer insights into patient data and optimize treatment plans.
- Success and Opportunity Identification: Bionic Insights organizes information into areas of success and opportunity, allowing physicians to quickly identify factors influencing glucose outcomes, reducing time spent on raw data interpretation and increasing meaningful patient interactions.
- Mission-Driven Innovation: Beta Bionics is committed to simplifying diabetes management through innovation, and the launch of Bionic Insights marks a significant step in improving patient quality of life and treatment effectiveness.
See More
Faruqi & Faruqi Investigates Beta Bionics for Investor Losses
- Investor Loss Investigation: Faruq & Faruqi, LLP is investigating potential claims against Beta Bionics, aiming to provide legal support for affected investors to help them assert their rights.
- Legal Consultation Opportunity: The firm encourages investors who suffered significant losses in Beta Bionics stock or options to contact partner Josh Wilson directly, offering consultation services to explore legal options and enhance investor awareness of their rights.
- Industry Background: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in the securities law field.
- National Reach: With offices in New York, Pennsylvania, California, and Georgia, the firm demonstrates its capability to provide legal services nationwide, enabling support for investors across various regions.
See More
Faruqi & Faruqi Investigates Beta Bionics for Investor Losses
- Investor Loss Focus: Faruq & Faruq's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Beta Bionics (NASDAQ: BBNX) to reach out directly, indicating the firm's commitment to protecting investor rights.
- Legal Rights Discussion: Investors who have incurred losses in Beta Bionics stock or options can call the hotline at 877-247-4292 or 212-983-9330 (Ext. 1310) for consultation, demonstrating the firm's dedication to client support and service.
- Company Background: Founded in 1995, Faruq & Faruq has recovered hundreds of millions of dollars for investors, showcasing its extensive experience and successful track record in securities law, which enhances investor trust in its capabilities.
- National Legal Services: With headquarters in New York and offices in Pennsylvania, California, and Georgia, the firm demonstrates its ability to provide legal services nationwide, further expanding its client base and market influence.
See More
Faruqi & Faruqi Investigates Beta Bionics Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Beta Bionics, indicating that the company may face legal risks as it seeks to support investors who have suffered significant losses.
- Investor Rights Protection: The firm encourages investors who have incurred losses in Beta Bionics stock or options to contact partner Josh Wilson directly, demonstrating a commitment to safeguarding investor rights.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law.
- Contact Information Provided: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to ensure that affected investors receive timely legal advice and support.
See More
Faruqi & Faruqi Investigates Investor Losses in Beta Bionics
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Beta Bionics to provide legal support for investors who have suffered significant losses, indicating potential legal liabilities for the company.
- Investor Rights Protection: The firm encourages Beta Bionics investors to contact partner Josh Wilson directly, demonstrating its commitment to investor rights and offering legal consultation to help investors understand their options.
- Company Background Information: Beta Bionics is a publicly traded company on NASDAQ involved in the biotechnology sector, and investor losses may be related to operational or financial issues, impacting market confidence.
- Firm's Strength Showcase: Since its founding in 1995, Faruq & Faruq LLP has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in the securities law field.
See More
Faruqi & Faruqi Investigates Beta Bionics After 37% Stock Plunge
- Stock Plunge: Beta Bionics' shares fell approximately 37% on January 9, 2026, primarily due to the company's expectation of fewer patient starts in Q4 than analysts estimated, which undermined investor confidence and may lead to legal action.
- Legal Investigation: Faruq & Faruqi, LLP is investigating whether Beta Bionics issued misleading statements or failed to disclose information critical to investors, aiming to protect investor rights and pursue potential compensation.
- Investor Losses: The law firm encourages investors who suffered significant losses to contact their securities litigation partner, Josh Wilson, directly, indicating the firm's commitment to supporting investors in addressing their losses.
- Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which further enhances investor trust in its investigation.
See More
